Atorvastatin Combined with Low-Dose Dexamethasone Treatment Protects Endothelial Function Impaired by Chronic Subdural Hematoma via the Transcription Factor KLF-2.
Yueshan FanDong WangChenxu RaoYing LiHongtao RongZengguang WangJianning ZhangPublished in: Drug design, development and therapy (2020)
Coculture with hematoma samples decreased KLF-2 expression in human cerebral endothelial cells. Combination therapy with atorvastatin and low-dose dexamethasone counteracted hematoma-induced KLF-2 suppression in human cerebral endothelial cells to attenuate robust endothelial inflammation and permeability. KLF-2 plays an important role in drug therapy for CSDH and may become the key factor in treatment and prognosis.
Keyphrases
- endothelial cells
- low dose
- high glucose
- transcription factor
- combination therapy
- high dose
- vascular endothelial growth factor
- subarachnoid hemorrhage
- drug induced
- poor prognosis
- emergency department
- diabetic rats
- blood brain barrier
- genome wide identification
- induced pluripotent stem cells
- replacement therapy
- stress induced
- electronic health record
- cerebral blood flow